Repligen (NASDAQ:RGEN) Releases FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 1.500-1.580 for the period, compared to the consensus EPS estimate of 1.430. The company issued revenue guidance of $630.0 million-$639.0 million. Repligen also updated its FY24 guidance to $1.50-1.58 EPS.

Wall Street Analyst Weigh In

RGEN has been the topic of several research reports. Benchmark restated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Finally, UBS Group reduced their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Performance

NASDAQ RGEN opened at $139.51 on Tuesday. The company’s 50 day simple moving average is $141.56 and its two-hundred day simple moving average is $145.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The stock has a market capitalization of $7.81 billion, a PE ratio of -3,487.75, a P/E/G ratio of 4.04 and a beta of 0.96.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is currently owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.